Vice President Head of Medical Affairs

Fresenius; Eysins; Remote; CHF 260,000 - 420,000; Full time

Job summary

Fresenius is seeking a senior Medical Affairs leader to define and drive the transformed function from educational activities to strategic access activation and insight leadership.

You will guide portfolio assessment, build scorecards for executives, and lead cross-functional collaboration across R&D, Commercial, Market Access and Regulatory to align on strategy and launch readiness.

Qualifications

• Proven leadership in Medical Affairs transformation and operating-model evolution.
• Strong understanding of biologics and biosimilars environment, including tender and access considerations.
• Deep expertise in KOL engagement, medical insights and evidence generation.

Responsibilities

• Define and lead evolved Medical Affairs vision and transformation roadmap.
• Support portfolio selection with medical input on context and relevance.
• Build scorecards for leadership with rapid, decision-oriented views.
• Lead strategic planning of KOL influence mapping across markets.
• Position Medical Affairs activities to key decision-makers by market archetype.
• Establish knowledge operations with AI-assisted synthesis and monthly insights cycle.

Skills

Medical Affairs leadership

Transformation leadership

Cross-functional leadership

Market access

KOL engagement

Evidence generation

AI synthesis

Knowledge management

Stakeholder influence

Education

MD/PhD

Tools

Microsoft Office

AI tools

Job description

Responsibilities / Duties:

• Define and lead the evolved Medical Affairs vision, operating model and transformation roadmap, shifting the function from primarily late-stage scientific education to strategic access activation and insight leadership.
• Support portfolio selection and new-molecule assessment by ensuring timely medical input on therapeutic-area context, clinical relevance, treatment algorithms, competitive disruptors, patient flows, unmet needs and biosimilar opportunity.
• Build and maintain reusable therapeutic-area scorecards and molecule scorecards that provide non-specialist leadership, portfolio, commercial and market-access stakeholders with rapid, critical and decision-oriented views.
• Lead the strategic planning of KOL influence mapping (physician/pharmacists/other HCPs) by optimizing global and country specific contribution with targeted local execution, ensuring country activities are focused where Medical Affairs can shape access, adoption and patient impact.
• Position Medical Affairs activities towards the relevant decision makers adjusting it to each market archetype, including pharmacists, procurement bodies, physicians and KOLs, depending on who drives access and adoption.
• Establish scalable knowledge, competitive-intelligence and medical-insight operations, including a written knowledge base, AI-assisted synthesis and a structured monthly insight cycle from field and congress activity to global action.
• Launch and oversee the India SSC Medical Affairs support model to reduce administrative burden, strengthen knowledge management and increase the capacity of global and country experts to focus on strategic priorities.
• Partner cross-functionally with Commercial, MSP, Market Access, Portfolio, Clinical Development, Regulatory, Safety, R& D leadership and BMT members to integrate Medical Affairs input into brand strategy, portfolio choices and launch readiness.
• Lead brand and lifecycle medical strategy at global level and ensure appropriate contribution to country execution, including scientific exchange, KOL engagement, congress strategy, insight generation and access-support materials in compliance with applicable standards.
• Develop, energize and retain a high-performing Medical Affairs organization with the agility, market understanding, transformation mindset and scientific credibility required for the next phase of BU Biopharma growth.
• Manage the Medical Affairs budget and resource allocation, including travel/congress investment, portfolio support, SSC operations and potential centralization of global/country Medical Affairs cost reporting under the FKSBS R& D P&L, as approved.
• Define and track transformation KPIs, including scorecard delivery, insight submission quality and cycle time, actionability of insights, priority-country/TA coverage, stakeholder impact, budget discipline and organizational engagement.
• Act as a credible internal and external ambassador for Fresenius Kabi Medical Affairs, ensuring ethics, compliance, scientific integrity and patient focus in all activities.
• Strategic Global Medical Affairs leadership in biosimilars or biologics across development, launch and lifecycle.
• Deep understanding of market access, tender environments, pharmacist/procurement ecosystems, - and country-specific market archetypes.
• Portfolio and asset-assessment capability, including treatment algorithms, unmet need, patient flow, competitive landscape, disruptors, product positioning and biosimilar opportunity evaluation.
• Ability to develop TA specific and TA agnostic Medical Affairs capabilities and translate complex medical information into concise, decision-oriented scorecards and executive recommendations.
• Strong cross-functional leadership across R&D, Commercial, MSP, Market Access, Portfolio, Clinical, Regulatory and Safety stakeholders.
• Transformation leadership, organizational change management, agile ways of working and ability to challenge legacy Medical Affairs approaches constructively.
• Medical insight generation, knowledge management, competitive intelligence, digital/AI-enabled synthesis and KPI-driven operational excellence.
• People leadership, talent development, engagement, communication, stakeholder influence and budget/resource management.
• Knowledge in several therapeutic areas

Education:

MD, PharmD, and/or PhD, or equivalent advanced scientific/medical qualification.

Qualification and Experience Requirements:

Strategic & Enterprise Leadership Capabilities

• Proven leadership in Medical Affairs transformation and operating-model evolution, including organizational capability building, portfolio and asset assessment, launch readiness, lifecycle strategy, and cross-functional governance.
• Strong understanding of the biologics and biosimilars environment, including competitive dynamics, tender and access considerations, and the increasingly important roles of physicians, pharmacists, procurement stakeholders, and other healthcare decision-makers.
• Deep expertise in KOL engagement, medical insights, evidence generation, and competitive intelligence, with the ability to translate external insights into actionable strategic priorities.
• Demonstrated success designing and leading high-impact medical initiatives that influence clinical practice and stakeholder decision-making, including engagement with physician KOLs, pharmacists, nurse practitioners, and other healthcare professionals.
• Proven ability to develop scientifically rigorous and pragmatic solutions to complex clinical, evidence, and business challenges, connecting scientific strategy with organizational priorities and patient needs.

Digital & Communication Capabilities

• High proficiency in English; additional languages are an asset.
• Strong digital fluency, including advanced use of Microsoft Office and the ability to leverage digital platforms, real-world and scientific databases, and AI-enabled tools to accelerate knowledge management, evidence assessment, insight synthesis, and strategic decision-making.